Share Price and Basic Stock Data
Last Updated: November 26, 2025, 7:08 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Chemo Pharma Laboratories Ltd operates within the pharmaceuticals sector, focusing on the production and distribution of pharmaceutical products. The company reported a price of ₹110 and a market capitalization of ₹16.6 Cr. A concerning aspect of Chemo Pharma’s business is its sales performance, which has consistently remained at ₹0 across all reported quarters from March 2022 through December 2024. This lack of revenue generation raises significant questions regarding the company’s operations and market strategy. The absence of sales could be indicative of underlying issues such as regulatory challenges, production inefficiencies, or market competition, which may hinder its ability to capture market share in a sector that is typically characterized by growth and innovation. Moreover, the company’s operating profit margin (OPM) is absent, further emphasizing the lack of operational performance. As such, the overall business outlook appears bleak without any tangible revenue streams to support growth or expansion.
Profitability and Efficiency Metrics
Chemo Pharma’s profitability metrics indicate persistent challenges, with a net profit reported at -₹12 lakh for the trailing twelve months (TTM). The company has recorded negative operating profits across all quarters leading to a cumulative operating loss of ₹12 lakh. The return on equity (ROE) stands at a mere 3.47%, and the return on capital employed (ROCE) is at 5.17%, both of which are below industry averages. This underperformance highlights inefficiencies in utilizing equity and capital to generate returns. Additionally, the lack of interest expenses indicates a potential absence of debt financing, which could limit growth opportunities. The company’s financial health is further reflected in its earnings per share (EPS) which fluctuated, with a reported EPS of ₹-2.27 for March 2025. The combination of these metrics suggests that Chemo Pharma is struggling to achieve profitability and operational efficiency, which could deter potential investors and stakeholders.
Balance Sheet Strength and Financial Ratios
Chemo Pharma Laboratories Ltd’s balance sheet presents a concerning picture, characterized by a price-to-book value (P/BV) ratio of 0.72x, indicating that the market values the company at less than its book value. This could be a reflection of market skepticism regarding the company’s future profitability and growth potential. The absence of reported reserves and borrowings suggests a lack of financial leverage and investment in growth opportunities, which may hinder the company’s ability to scale operations. Moreover, the interest coverage ratio (ICR) is not applicable, signaling that the company has not incurred any interest expenses, which raises questions about its financing strategies. The efficiency metrics, particularly the return on capital employed, which stood at 5.17%, are low compared to sector standards, indicating that the firm is not effectively using its capital to generate profits. Overall, the balance sheet lacks the robustness typically expected in a healthy pharmaceutical company, potentially limiting future investment and operational flexibility.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Chemo Pharma reflects a diverse ownership structure, with promoters holding 27.89% of the shares, while institutional investors, including foreign institutional investors (FIIs), have not reported any holdings. Domestic institutional investors (DIIs) hold a minimal 0.17%, and the public holds a significant 71.75% of the shares. The number of shareholders has shown slight fluctuations, standing at 6,409 as of December 2024. This distribution may indicate a lack of confidence from institutional investors, which is often a red flag for potential market participants. The relatively high public shareholding could lead to volatility in stock performance, especially in the absence of solid operational results. The continuous decline in DII participation may signal skepticism about the company’s strategic direction and financial health, further impacting investor sentiment and confidence in the stock moving forward.
Outlook, Risks, and Final Insight
The outlook for Chemo Pharma Laboratories Ltd remains precarious, primarily due to its consistent inability to generate sales and the ongoing losses reported. The lack of revenue streams poses significant risks, including operational sustainability and the potential for continued financial deterioration. Key strengths include its established presence in the pharmaceuticals sector and a relatively low P/BV ratio which may attract value investors if operational turnaround strategies are successfully implemented. However, the risks associated with regulatory challenges, market competition, and an unfavourable financial performance overshadow these strengths. Should the company manage to address its operational inefficiencies and successfully re-enter the market with viable products, there could be potential for recovery. On the contrary, if current trends persist, Chemo Pharma may face challenges in maintaining its operational viability in a competitive landscape.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Chemo Pharma Laboratories Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 162 Cr. | 129 | 247/84.3 | 35.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,538 Cr. | 417 | 479/192 | 94.0 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.9 Cr. | 47.0 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 41.5 Cr. | 28.3 | 29.1/17.0 | 98.8 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,356.00 Cr | 1,182.92 | 52.67 | 202.40 | 0.35% | 16.24% | 14.95% | 6.10 |
Quarterly Result
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Expenses | 0.18 | 0.12 | 0.05 | 0.02 | 0.02 | 0.05 | 0.02 | 0.02 | 0.10 | 0.05 | 0.02 | 0.02 | 0.02 |
| Operating Profit | -0.18 | -0.12 | -0.05 | -0.02 | -0.02 | -0.05 | -0.02 | -0.02 | -0.10 | -0.05 | -0.02 | -0.02 | -0.02 |
| OPM % | |||||||||||||
| Other Income | 0.13 | -0.38 | 0.59 | 0.19 | -0.10 | 0.43 | 0.46 | 0.70 | 0.25 | 0.30 | 0.63 | -0.15 | -0.16 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.05 | -0.50 | 0.54 | 0.17 | -0.12 | 0.38 | 0.44 | 0.68 | 0.15 | 0.25 | 0.61 | -0.17 | -0.18 |
| Tax % | -400.00% | 0.00% | 0.00% | 0.00% | 25.00% | 0.00% | 0.00% | 0.00% | 293.33% | 0.00% | 0.00% | 0.00% | 88.89% |
| Net Profit | 0.14 | -0.50 | 0.53 | 0.16 | -0.15 | 0.38 | 0.44 | 0.68 | -0.29 | 0.25 | 0.61 | -0.17 | -0.34 |
| EPS in Rs | 0.93 | -3.33 | 3.53 | 1.07 | -1.00 | 2.53 | 2.93 | 4.53 | -1.93 | 1.67 | 4.07 | -1.13 | -2.27 |
Last Updated: May 31, 2025, 6:32 am
Below is a detailed analysis of the quarterly data for Chemo Pharma Laboratories Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Sales, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Expenses, as of Mar 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.02 Cr..
- For Operating Profit, as of Mar 2025, the value is -0.02 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded -0.02 Cr..
- For OPM %, as of Mar 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00%.
- For Other Income, as of Mar 2025, the value is -0.16 Cr.. The value appears to be declining and may need further review. It has decreased from -0.15 Cr. (Dec 2024) to -0.16 Cr., marking a decrease of 0.01 Cr..
- For Interest, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Depreciation, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 0.00 Cr..
- For Profit before tax, as of Mar 2025, the value is -0.18 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.18 Cr., marking a decrease of 0.01 Cr..
- For Tax %, as of Mar 2025, the value is 88.89%. The value appears to be increasing, which may not be favorable. It has increased from 0.00% (Dec 2024) to 88.89%, marking an increase of 88.89%.
- For Net Profit, as of Mar 2025, the value is -0.34 Cr.. The value appears to be declining and may need further review. It has decreased from -0.17 Cr. (Dec 2024) to -0.34 Cr., marking a decrease of 0.17 Cr..
- For EPS in Rs, as of Mar 2025, the value is -2.27. The value appears to be declining and may need further review. It has decreased from -1.13 (Dec 2024) to -2.27, marking a decrease of 1.14.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: November 15, 2025, 3:40 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Expenses | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 12 |
| Operating Profit | -0 | -0 | -0 | -0 | -0 | -1 | -0 | -0 | -0 | -0 | -0 | -0 | -12 |
| OPM % | -2,221% | ||||||||||||
| Other Income | 0 | 0 | 0 | 6 | 1 | 1 | 1 | 1 | 1 | 0 | 2 | 1 | -0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0 | 0 | 0 | 5 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | -12 |
| Tax % | 19% | 26% | 31% | 12% | 86% | 19% | 16% | 19% | -56% | 38% | 27% | 33% | |
| Net Profit | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | -12 |
| EPS in Rs | 1.60 | 1.87 | 1.47 | 31.20 | 0.67 | 1.40 | 2.80 | 1.67 | 3.73 | 0.33 | 8.00 | 2.27 | -81.46 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2017-2018 | 2022-2023 | 2024-2025 |
|---|---|---|---|
| YoY Net Profit Growth (%) | -100.00% | -100.00% | -100.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | 0.00% | 0.00% |
Chemo Pharma Laboratories Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 3 years from 2017-2018 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -4% |
| 3 Years: | -4% |
| TTM: | -1184% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 64% |
| 3 Years: | 54% |
| 1 Year: | 65% |
| Return on Equity | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 4% |
| 3 Years: | 4% |
| Last Year: | 3% |
Last Updated: September 5, 2025, 2:56 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | ||||||||||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | ||||||||||||
| Working Capital Days | ||||||||||||
| ROCE % | 7% | 8% | 6% | 4% | 8% | 3% | 5% | 3% | 1% | 1% | 13% | 5% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 16 |
|---|---|
| FaceValue | 10.00 |
| Basic EPS (Rs.) | -9.66 |
| Diluted EPS (Rs.) | -9.66 |
| Cash EPS (Rs.) | -9.66 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.49 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.49 |
| PBDIT / Share (Rs.) | -8.98 |
| PBIT / Share (Rs.) | -8.98 |
| PBT / Share (Rs.) | -8.98 |
| Net Profit / Share (Rs.) | -9.66 |
| NP After MI And SOA / Share (Rs.) | -9.66 |
| Return on Networth / Equity (%) | -39.44 |
| Return on Capital Employeed (%) | -35.51 |
| Return On Assets (%) | -37.44 |
| Current Ratio (X) | 28.82 |
| Quick Ratio (X) | 28.82 |
| Enterprise Value (Cr.) | 2.24 |
| EV / EBITDA (X) | -1.66 |
| Price / BV (X) | 0.72 |
| EarningsYield | -0.54 |
After reviewing the key financial ratios for Chemo Pharma Laboratories Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 16, the value is 10.00. This value is within the healthy range. No previous period data is available for comparison.
- For Basic EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Diluted EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Cash EPS (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 3. No previous period data is available for comparison.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 16, the value is 24.49. No previous period data is available for comparison.
- For PBDIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For PBIT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For PBT / Share (Rs.), as of Mar 16, the value is -8.98. This value is below the healthy minimum of 0. No previous period data is available for comparison.
- For Net Profit / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For NP After MI And SOA / Share (Rs.), as of Mar 16, the value is -9.66. This value is below the healthy minimum of 2. No previous period data is available for comparison.
- For Return on Networth / Equity (%), as of Mar 16, the value is -39.44. This value is below the healthy minimum of 15. No previous period data is available for comparison.
- For Return on Capital Employeed (%), as of Mar 16, the value is -35.51. This value is below the healthy minimum of 10. No previous period data is available for comparison.
- For Return On Assets (%), as of Mar 16, the value is -37.44. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Current Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 3. No previous period data is available for comparison.
- For Quick Ratio (X), as of Mar 16, the value is 28.82. This value exceeds the healthy maximum of 2. No previous period data is available for comparison.
- For Enterprise Value (Cr.), as of Mar 16, the value is 2.24. No previous period data is available for comparison.
- For EV / EBITDA (X), as of Mar 16, the value is -1.66. This value is below the healthy minimum of 5. No previous period data is available for comparison.
- For Price / BV (X), as of Mar 16, the value is 0.72. This value is below the healthy minimum of 1. No previous period data is available for comparison.
- For EarningsYield, as of Mar 16, the value is -0.54. This value is below the healthy minimum of 5. No previous period data is available for comparison.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Chemo Pharma Laboratories Ltd:
- Net Profit Margin: 0%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -35.51% (Industry Average ROCE: 16.24%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: -39.44% (Industry Average ROE: 14.95%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 0
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 28.82
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 52.67)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 0%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 5, Kumud Apartment CHS Ltd., Thane District Maharashtra 421301 | chemopharmalab@gmail.com http://www.thechemopharmalaboratoriesltd.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Bhavin Sheth | Executive Director & CEO |
| Mr. Ashok Somani | Executive Director & CFO |
| Mrs. Shanta Somani | Non Executive Director |
| Mr. Mathura Prasad Sharma | Independent Director |
| Mr. Toby Antony | Independent Director |
| Mr. Nandkumar Pareek | Independent Director |